Get the Stockscreener App
36.02
0.19%
0.07
Pre-market:
35.12
-0.90
-2.50%
Structure Therapeutics Inc Adr stock is traded at $36.02, with a volume of 1.14M.
It is up +0.19% in the last 24 hours and down -26.50% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$35.95
Open:
$35.35
24h Volume:
1.14M
Relative Volume:
1.49
Market Cap:
$2.57B
Revenue:
-
Net Income/Loss:
$-170.73M
P/E Ratio:
-13.38
EPS:
-2.6921
Net Cash Flow:
$-159.70M
1W Performance:
+2.62%
1M Performance:
-26.50%
6M Performance:
-23.43%
1Y Performance:
+40.54%
1-Day Range:
$34.43
$36.27
1-Week Range:
$34.41
$37.74
52-Week Range:
$24.54
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(650) 457-1978
Address
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
36.02 | 2.57B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Canaccord Genuity | Buy |
| Mar-26-26 | Initiated | Wolfe Research | Peer Perform |
| May-02-25 | Initiated | Citigroup | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Structure Therapeutics Inc. (GPCR) Stock Price, News, Quote & History - ca.finance.yahoo.com
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Zacks Investment Research
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Form 144 Structure Therapeutics Inc. For: 22 September By Investing.com - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Envista Holdings (NVST) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Planned $140K share sale by Structure Therapeutics (Nasdaq: GPCR) officer - Stock Titan
Structure Therapeutics Surges On Promising Obesity Drug Data - TipRanks
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious? - TradingView
Structure Therapeutics at Morgan Stanley conference: oral pipeline gains ground - Investing.com Canada
Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com India
Price-Driven Insight from (GPCR) for Rule-Based Strategy - news.stocktradersdaily.com
Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT) - The Globe and Mail
Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management - finance.yahoo.com
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences - finance.yahoo.com
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - stocktitan.net
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - finance.yahoo.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - TradingView
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - TradingView
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? - TradingView
Structure Therapeutics Slumps As Analysts Turn Sharply Bearish - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
HC Wainwright Has Bearish Forecast for GPCR Q3 Earnings - MarketBeat
Pacira Pharmaceuticals (PCRX) Receives a Sell from J.P. Morgan - theglobeandmail.com
Renaissance Technologies LLC Sells 59,400 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):